Naringenin has a chemoprotective effect in MDA‑MB‑231 breast cancer cells via inhibition of caspase‑3 and ‑9 activities

Wang,Rui; Wang,Junhai; Dong,Tianfu; Shen,Jun; Gao,Xitao; Zhou,Jun

doi:10.3892/ol.2018.9704

Naringenin has a chemoprotective effect in MDA‑MB‑231 breast cancer cells via inhibition of caspase‑3 and ‑9 activities

Authors:
- Rui Wang
- Junhai Wang
- Tianfu Dong
- Jun Shen
- Xitao Gao
- Jun Zhou
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, P.R. China, Department of Clinical Laboratory, Tai'an Cancer Hospital, Tai'an, Shandong 271000, P.R. China
Published online on: November 15, 2018 https://doi.org/10.3892/ol.2018.9704
Pages: 1217-1222

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the leading cause of cancer‑associated mortality in females. It has an incidence of 1.3 million per year, which increases by 2% annually. In China, breast cancer accounts for 12.2% of all cancer cases. The aim of the present study was to investigate the inhibitory effect of naringenin on triple‑negative breast cancer cells. Lactate dehydrogenase and MTT assay was used to investigate the inhibitory effect of naringenin on MDA‑MB‑231 cell viability. Naringenin reduced the viability of MDA‑MB‑231 cells by arresting the cell cycle at the G2 phase. Naringenin treatment not only influenced the phase of cell cycle arrest, but also induced apoptosis in a dose‑dependent manner. Naringenin treatment also resulted in a significant increase in caspase‑3 and caspase‑9 activity (P<0.001). Taken together, the results of the present study suggested that naringenin caused an inhibitory effect on MDA‑MB‑231 cells via induction of apoptosis and inhibition of caspase‑3 and ‑9 activity.

View Figures

View References

1	Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et al: The global burden of women's cancers: A grand challenge in global health. Lancet. 389:847–860. 2017. View Article : Google Scholar : PubMed/NCBI
2	Denny L, de Sanjose S, Mutebi M, Anderson BO, Kim J, Jeronimo J, Herrero R, Yeates K, Ginsburg O and Sankaranarayanan R: Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet. 389:861–870. 2017. View Article : Google Scholar : PubMed/NCBI
3	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in china. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in china, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	Cella D and Fallowfield LJ: Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 107:167–180. 2008. View Article : Google Scholar : PubMed/NCBI
6	Taylor CW and Kirby AM: Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol). 27:621–629. 2015. View Article : Google Scholar : PubMed/NCBI
7	Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, et al: Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 9:2392008. View Article : Google Scholar : PubMed/NCBI
8	Mohapatro SK, Dandapat MC and Padhi NC: Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. J Indian Med Assoc. 90:39–42. 1992.PubMed/NCBI
9	Dixon JM: Endocrine resistance in breast cancer. New J Sci. 1–27. 2014. View Article : Google Scholar
10	Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 1 Suppl 16:S1–S11. 2011. View Article : Google Scholar
11	Patel K, Singh GK and Patel DK: A review on pharmacological and analytical aspects of naringenin. Chin J Integr Med. 24:551–560. 2018. View Article : Google Scholar : PubMed/NCBI
12	Azuma T, Shigeshiro M, Kodama M, Tanabe S and Suzuki T: Supplemental naringenin prevents intestinal barrier defects and inflammation in colitic mice. J Nutr. 143:827–834. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
14	Ziegler RG, Anderson WF and Gail MH: Increasing breast cancer incidence in China: The numbers add up. J Natl Cancer Inst. 100:1339–1341. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 351:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
16	Yu ZG, Jia CX, Geng CZ, Tang JH, Zhang J and Liu LY: Risk factors related to female breast cancer in regions of northeast china: A 1:3 matched case-control population-based study. Chin Med J (Engl). 125:733–740. 2012.PubMed/NCBI
17	McPherson K, Steel CM and Dixon JM: Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321:624–628. 2000. View Article : Google Scholar : PubMed/NCBI
18	Stuckey A: Breast cancer: Epidemiology and risk factors. Clin Obstet Gynecol. 54:96–102. 2011. View Article : Google Scholar : PubMed/NCBI
19	Nikoletopoulou V, Markaki M, Palikaras K and Tavernarakis N: Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 1833:3448–3459. 2013. View Article : Google Scholar : PubMed/NCBI
20	Miao P, Sheng S, Sun X, Liu J and Huang G: Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy. IUBMB Life. 65:904–910. 2013. View Article : Google Scholar : PubMed/NCBI
21	Crowley LC, Christensen ME and Waterhouse NJ: Measuring survival of adherent cells with the Colony-forming assay. Cold Spring Harb Protoc. 2016:721–724. 2016. View Article : Google Scholar
22	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
23	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: A link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
24	Kerr JF, Winterford CM and Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:2013–2026. 1994. View Article : Google Scholar : PubMed/NCBI
25	Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell. 3:17–22. 2003. View Article : Google Scholar : PubMed/NCBI
26	Han X, Ren D, Fan P, Shen T and Lou H: Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharmacol. 581:47–53. 2008. View Article : Google Scholar : PubMed/NCBI
27	Arul D and Subramanian P: Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 19:763–770. 2013. View Article : Google Scholar : PubMed/NCBI
28	Park HJ, Choi YJ, Lee JH and Nam MJ: Naringenin causes ASK1-induced apoptosis via reactive oxygen species in human pancreatic cancer cells. Food Chem Toxicol. 99:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
29	Fiandalo MV and Kyprianou N: Caspase control: Protagonists of cancer cell apoptosis. Exp Oncol. 34:165–175. 2012.PubMed/NCBI
30	Olsson M and Zhivotovsky B: Caspases and cancer. Cell Death Differ. 18:1441–1449. 2011. View Article : Google Scholar : PubMed/NCBI
31	Salvesen GS and Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell. 91:443–446. 1997. View Article : Google Scholar : PubMed/NCBI
32	Hensley P, Mishra M and Kyprianou N: Targeting caspases in cancer therapeutics. Biol Chem. 394:831–843. 2013. View Article : Google Scholar : PubMed/NCBI